Amyl Therapeutics Closes €18.3 million Series A Financing to Develop Novel Therapies for Amyloidosis
Amyl Therapeutics (‘Amyl’), a preclinical stage biotechnology company developing its amyloid fibrils specific technology platform named ClariTY for the treatment of all forms of Amyloidosis, today announced that it has successfully closed a €18.3 million Series A financing. The funding round comprises €8.6 million in equity led by Noshaq – a regional Belgian private-public fund – with support from Merieux Participations, Sambrinvest and other private investors; and €9.7 million in non-dilutive funding from the DG06 – a key policy-design and implementing body for research and innovation policy in the Walloon region of Belgium.
Dr. Pierre Vandepapelière, Chief Executive Officer (CEO) and Chief Medical Officer (CMO), and Dr. Karine Goraj, Chief Scientific Officer (CSO), both veterans in the field of pharmaceutical development, will lead the team.
Amyl will use the funds to progress the discovery and preclinical development of therapeutic candidates that are able to target multiple misfolded proteins implicated in both progressive peripheral and neurodegenerative rare diseases. With the funds raised Amyl Therapeutics expects to generate strong preclinical proof of concept for its lead therapeutic candidates and to set up a production process as part of its clinical readiness.
Amyloidosis is a group of diseases characterized by an endogenous production of misfolded proteins that aggregate as insoluble amyloid fibrils and form deposits in various organs and tissues, resulting in organ dysfunction, serious morbidity and even death. More than 30 of such proteins have been identified as amyloid precursors in humans. These are grouped into localized forms, and systemic ones with the most common types of systemic amyloidosis being: “light chain” (AL) amyloidosis, hereditary and old age transthyretin (ATTR) amyloidosis and inflammatory amyloidosis with protein A (AA).
There are currently between 30,000 and 45,000 patients suffering from AL amyloidosis in the USA and Europe, which is the most common form of the disease, affecting about 70% of all patients diagnosed with systemic amyloidosis. At present, there is no effective treatment for established amyloidosis diseases.
Dr. Pierre Vandepapelière, Co-Founder, CEO and CMO of Amyl Therapeutics, said “We are excited to have raised this Series A financing from a syndicate of high-quality and international investors. The ClariTY platform offers the unique opportunity to generate therapeutic candidates able to target all amyloid fibril deposits, a key cause of amyloidosis. We believe novel therapies with this profile will represent a major advance in the treatment of diseases caused by amyloid fibrils and will have a significant competitive advantage.”
Dr. Karine Goraj, CSO of Amyl Therapeutics, said “The ClariTY platform provides a unique and powerful tool for treating amyloidosis, for which treatment options are very limited today. By developing therapeutic solutions that could not only stop progression but also remove existing amyloid deposits in organs, we hope to be part of the solution to treat a large populations of Amyloidosis patients.”
Gaetan Servais, CEO of Noshaq, added “Our equity investment in Amyl represents a significant opportunity to participate in the development of what we believe is an exciting technology for the treatment of Amyloidosis. We are pleased to welcome the Company to set up its operations in Liege with the objective of fostering collaborations with other players in the region.”
Dr. Valérie Calenda, Managing Partner at Merieux Equity Partners, commented “We are pleased to support such a great team and to get the opportunity to bring new drug candidates against these diseases into clinical development.”
“Investing in Amyl Therapeutics alongside Noshaq and other partner funds was a no brainer. We have faith in the management and their team to find effective treatments to tackle all forms of Amyloidosis,” adds Helena Pozios, Head of Biotech at Sambrinvest.
Following the closing of the financing, Dr. Pierre Vandepapelière (Amyl’s Co-Founder, CEO and CMO), Florent Gros (Amyl’s Co-Founder and Chairman), Dr. Valérie Calenda (Managing Partner at Merieux Equity Partners), Kenneth Buckfire (President of Miller Buckfire & Co.) and Amel Tounsi (Investment Manager at Noshaq) have joined the Board of Directors.
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more